Skip to main content

Advertisement

SpringerLink
Log in

Prognostic significance of vasohibin-1 and vasohibin-2 immunohistochemical expression in gastric cancer

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

It was recently identified that the vasohibin family may regulate angiogenesis through suppression by the vasohibin-1 gene and promotion by the vasohibin-2 gene. We assessed vasohibin expression in gastric cancer patients and its effect on their prognosis.

Methods

We evaluated vasohibin immunohistochemical expression in 210 patients with gastric cancer, who underwent radical surgery. The patients were divided first into a vasohibin-1-positive group and a vasohibin-1-negative group, and then into groups with high or low vasohibin-2 expression, to allow us to investigate the clinicopathological factors of prognosis retrospectively.

Results

There were 139 patients in the vasohibin-1-positive group and 71 patients in the vasohibin-1-negative group, among which there were and 108 with high vasohibin-2 expression and 102 with low vasohibin-2 expression. Vasohibin-1 was associated with Ly (P = 0.003) and pT (P = 0.037), whereas vasohibin-2 was associated with Ly (P < 0.001), V (P < 0.001) and pStage (P < 0.001). Overall, cancer-specific and relapse-free survival rates were lower in the vasohibin-1-positive (P = 0.034, P < 0.001, P = 0.002, respectively) and high vasohibin-2 expression (P = 0.004, P = 0.003, P < 0.001, respectively) groups. Multivariate analysis revealed that vasohibin-1 expression was associated with cancer-specific (P = 0.014, hazard ratio [HR] 4.454) and relapse-free (P = 0.035, HR 2.557) survival and vasohibin-2 expression tended to influence relapse-free survival (P = 0.051, HR 2.061). Grouping patients by vasohibin expression status combinations showed correlation among their expressions (P = 0.005). Overall, cancer-specific and relapse-free survival rates were lowest in the vasohibin-1-positive and high vasohibin-2 expression group.

Conclusion

Our findings demonstrate that vasohibin-1 and vasohibin-2 could be novel biomarkers for predicting gastric cancer prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64.

    Article  Google Scholar 

  2. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75.

    Article  Google Scholar 

  3. Gotoda T. Endoscopic resection of early gastric cancer. Gastric Cancer. 2007;10:1–11.

    Article  Google Scholar 

  4. Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc. 1994;4:146–8.

    CAS  PubMed  Google Scholar 

  5. Bandoh T, Shiraishi N, Yamashita Y, Terachi T, Hashizume M, Akira S, et al. Endoscopic surgery in Japan: the 12th national survey (2012–2013) by the Japan Society for Endoscopic Surgery. Asian J Endosc Surg. 2017;10:345–53.

    Article  Google Scholar 

  6. Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer. 2018;21:144–54.

    Article  Google Scholar 

  7. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.

    Article  CAS  Google Scholar 

  8. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18:5992–6000.

    Article  CAS  Google Scholar 

  9. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019. https://doi.org/10.1200/JCO.18.01265.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sato Y. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Int J Clin Oncol. 2008;8:200–6.

    Article  Google Scholar 

  11. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.

    Article  CAS  Google Scholar 

  12. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579–91.

    Article  CAS  Google Scholar 

  13. Sato Y, Sonoda H. The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27:37–41.

    Article  CAS  Google Scholar 

  14. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest. 2004;114:898–907.

    Article  CAS  Google Scholar 

  15. Shibuya T, Watanabe K, Yamashita H, Shimizu K, Miyashita H, Abe M, et al. Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. Arterioscler Thromb Vasc Biol. 2006;26:1051–7.

    Article  CAS  Google Scholar 

  16. Hosaka T, Kimura H, Heishi T, Suzuki Y, Miyashita H, Ohta H, et al. Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am J Pathol. 2009;175:430–9.

    Article  Google Scholar 

  17. Koyanagi T, Saga Y, Takahashi Y, Suzuki Y, Suzuki M, Sato Y. Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells. Oncol Lett. 2013;5:1058–62.

    Article  CAS  Google Scholar 

  18. Miyazaki Y, Kosaka T, Mikami S, Kikuchi E, Tanaka N, Maeda T, et al. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin Cancer Res. 2012;18:4145–53.

    Article  CAS  Google Scholar 

  19. Ninomiya Y, Ozawa S, Oguma J, Kazuno A, Nitta M, Kajiwara H, et al. Expression of vasohibin-1 and -2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus. Oncol Lett. 2018;16:5265–74.

    PubMed  PubMed Central  Google Scholar 

  20. Gullo I, Carneiro F, Oliveira C, Almeida GM. Heterogeneity in gastric cancer: from pure morphology to molecular classifications. Pathobiology. 2018;85:50–63.

    Article  Google Scholar 

  21. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138–40.

    CAS  PubMed  Google Scholar 

  22. Kim JC, Kim KT, Park JT, Kim HJ, Sato Y, Kim HS. Expression of vasohibin-2 in pancreatic ductal adenocarcinoma promotes tumor progression and is associated with a poor clinical outcome. Hepatogastroenterology. 2015;62:251–6.

    CAS  PubMed  Google Scholar 

  23. Tamaki K, Moriya T, Sato Y, Ishida T, Maruo Y, Yoshinaga K, et al. Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis. Cancer Sci. 2009;100:88–94.

    Article  CAS  Google Scholar 

  24. Yoshinaga K, Ito K, Moriya T, Nagase S, Takano T, Niikura H, et al. Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer. Cancer Sci. 2008;99:914–9.

    Article  CAS  Google Scholar 

  25. Yoshinaga K, Ito K, Moriya T, Nagase S, Takano T, Niikura H, et al. Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas. Cancer Sci. 2011;102:446–51.

    Article  CAS  Google Scholar 

  26. Murakami K, Kasajima A, Kawagishi N, Sekiguchi S, Fujishima F, Watanabe M, et al. The prognostic significance of vasohibin 1-associated angiogenesis in patients with hepatocellular carcinoma. Hum Pathol. 2014;45:589–97.

    Article  CAS  Google Scholar 

  27. Kitajima T, Toiyama Y, Tanaka K, Saigusa S, Kobayashi M, Inoue Y, et al. Vasohibin-1 increases the malignant potential of colorectal cancer and is a biomarker of poor prognosis. Anticancer Res. 2014;34:5321–9.

    PubMed  Google Scholar 

  28. Zhang T, Yu TT, Zhang DM, Hou XM, Liu XJ, Zhao D, et al. Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer. Med Oncol. 2014;31:963.

    Article  Google Scholar 

  29. Mikami S, Oya M, Kosaka T, Mizuno R, Miyazaki Y, Sato Y, et al. Increased vasohibin-1 expression is associated with metastasis and poor prognosis of renal cell carcinoma patients. Lab Invest. 2017;97:854–62.

    Article  CAS  Google Scholar 

  30. Torii C, Hida Y, Shindoh M, Akiyama K, Ohga N, Maishi N, et al. Vasohibin-1 as a novel prognostic factor for head and neck squamous cell carcinoma. Anticancer Res. 2017;37:1219–25.

    Article  CAS  Google Scholar 

  31. Kobayashi H, Kosaka T, Mikami S, Miyazaki Y, Matsumoto K, Kikuchi E, et al. Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer. Oncotarget. 2017;9:10203–100.

    Article  Google Scholar 

  32. Kosaka T, Miyazaki Y, Miyajima A, Mikami S, Hayashi Y, Tanaka N, et al. The prognostic significance of vasohibin-1 expression in patients with prostate cancer. Br J Cancer. 2013;108:2123–9.

    Article  CAS  Google Scholar 

  33. Sano R, Kanomata N, Suzuki S, Shimoya K, Sato Y, Moriya T, et al. Vasohibin-1 is a poor prognostic factor of ovarian carcinoma. Tohoku J Exp Med. 2017;243:107–14.

    Article  CAS  Google Scholar 

  34. Takahashi Y, Koyanagi T, Suzuki Y, Saga Y, Kanomata N, Moriya T, et al. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Mol Cancer Res. 2012;10:1135–46.

    Article  CAS  Google Scholar 

  35. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.

    Article  CAS  Google Scholar 

  36. Norita R, Suzuki Y, Furutani Y, Takahashi K, Yoshimatsu Y, Podyma-Inoue KA, et al. Vasohibin-2 is required for epithelial–mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-beta signaling. Cancer Sci. 2017;108:419–26.

    Article  CAS  Google Scholar 

  37. Suzuki Y, Kitahara S, Suematsu T, Oshima M, Sato Y. Requisite role of vasohibin-2 in spontaneous gastric cancer formation and accumulation of cancer-associated fibroblasts. Cancer Sci. 2017;108:2342–51.

    Article  CAS  Google Scholar 

  38. Shen Z, Kauttu T, Seppänen H, Vainionpää S, Ye Y, Wang S, et al. Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs. Med Oncol. 2012;29:2718–26.

    Article  CAS  Google Scholar 

  39. Olivera-Severo D, Uberti AF, Marques MS, Pinto MT, Gomez-Lazaro M, Figueiredo C, et al. A new role for helicobacter pylori urease: contributions to angiogenesis. Front Microbiol. 2017;8:398–407.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Mr. Noboru Kawabe, Ms. Maki Niioka, and Ms. Izu Inada for their support.

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1143, Japan

    Hitoshi Hara, Soji Ozawa, Yamato Ninomiya, Miho Yamamoto, Mika Ogimi, Kazuhito Nabeshima & Kenji Nakamura

  2. Department of Pathology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1143, Japan

    Hiroshi Kajiwara & Naoya Nakamura

  3. Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-9575, Japan

    Yasufumi Sato

Authors
  1. Hitoshi Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soji Ozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yamato Ninomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miho Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mika Ogimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhito Nabeshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenji Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroshi Kajiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Naoya Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasufumi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Soji Ozawa.

Ethics declarations

Conflict of interest

We have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hara, H., Ozawa, S., Ninomiya, Y. et al. Prognostic significance of vasohibin-1 and vasohibin-2 immunohistochemical expression in gastric cancer. Surg Today 50, 1530–1543 (2020). https://doi.org/10.1007/s00595-020-02040-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-020-02040-4

Keywords

Search

Navigation